This document, globally recognized as the authoritative guideline for liquid sterilizing filtration, has been comprehensively updated. It covers everything from filter selection, validation, and usage to integrity testing and sterilization. It aims to provide a solid scientific basis and methodological guidance for selecting and validating liquid filters, reflecting current best practices and regulatory expectations.
Swipe up to view the table of contents
12.0 Appendix III: Integrity Test Troubleshooting Guide
13.0 Appendix Refere
Document Interpretation:
The document covers filter selection, validation, usage, integrity testing, and sterilization, forming a complete technical framework. It also expands its scope to include emerging fields such as traditional pharmaceuticals, biologics, and Advanced Therapy Medicinal Products (ATMPs).
Terminology Revolution: Clear Distinction of Three Key Concepts Ends Industry Confusion
0.2 μm or 0.22 μm Rated Filter: The pore size of these filters merely indicates a nominal rating of 0.2 or 0.22 microns; it does not mean they necessarily possess sterilizing capability. Many filters on the market, although rated at 0.22 μm, are only used for bioburden control and have not passed sterilizing validation. One cannot assume a filter is sterilizing-grade simply because it is labeled "0.22 μm."
Sterilizing-Grade Filter: The manufacturer has proven through standard testing (ASTM F838) that it can completely retain ≥ 107 CFU/cm2 of Brevundimonas diminuta. This is the filter's "factory qualification," indicating it is qualified for use in sterilizing processes. However, it does not guarantee it will sterilize in your specific process; whether it is "truly sterilizing" still requires validation.
Sterilizing Filter: Under specific process conditions, validation confirms it can truly achieve sterilization of the feed stream. Only after completing process-specific validation can the filter be called a "sterilizing filter." This means the same sterilizing-grade filter might act merely as a pre-filter in one process, but as a true sterilizing filter in another.
Full-Process Quality Control: New Framework Covers the Complete Filter Lifecycle
Emphasizes modern filter design and performance characteristics: Explicitly requires filters to withstand steam sterilization and irradiation, have low extractables/leachables, low non-specific adsorption, high throughput, and high flow rates.
Innovation in usage models: The document stipulates that filters are typically for single use. If reused, the impact of multiple sterilization cycles on integrity must be validated. It adds detailed guidance on single-use filters and systems, emphasizing their advantages: reducing cleaning validation, lowering cross-contamination risks, and improving operational safety.
Deepened Validation Requirements
Process-Specific Validation:
Emphasizes Quality by Design (QbD) principles.
Requires bacterial retention validation under worst-case conditions.
Adds validation requirements for redundant and dual filtration; the former only requires integrity testing of the primary filter, while the latter requires testing of both.
Extractables and Leachables:
Clearly distinguishes between Leachables and Extractables.
Emphasizes risk assessment and patient safety.
New Integrity Testing Regulations: PUPSIT and Product-Wet Integrity Testing
Standardization of method selection: Strengthens the correlation between integrity tests (e.g., Bubble Point, Diffusive Flow) and bacterial retention. It requires selecting the test method based on filter area (Bubble Point for small areas, Diffusive Flow for large areas).
Product-wet integrity testing: Requires converting aqueous test standards to product-specific standards using ratio methods (e.g., Bubble Point ratios) to ensure test conditions match the actual process.
Clarification of PUPSIT: Details the applicable scenarios and risk control for Pre-Use Post-Sterilization Integrity Testing (PUPSIT), noting it can detect potential damage to filters post-sterilization but requires weighing contamination risks. Provides an analysis and troubleshooting guide for integrity test failures.
Future-Oriented Compatibility Design
Expanded scope: For the first time, it comprehensively covers emerging fields like traditional pharmaceuticals, biologics, and Advanced Therapy Medicinal Products (ATMPs).
Sterilization methods: Updates filter sterilization methods to cover steam sterilization (SIP, Autoclave), irradiation sterilization (Gamma, X-ray), and gas sterilization (e.g., Ethylene Oxide). It clarifies validation requirements for these methods, such as controlling pressure differentials during steam sterilization to avoid membrane damage, considering polymer degradation risks during irradiation, and emphasizing the limitations and risks of repeatedly sterilizing filters.
Forward-looking layout for future pharma tech: Proposes additional considerations for filter validation regarding special products like ATMPs, LNPs (Lipid Nanoparticles), and viral vectors.
Conclusion: A Qualitative Leap from "Compliance" to "Science"
Understanding and implementing the new regulations means re-evaluating existing filtration processes, validation strategies, and quality systems. Companies that can quickly adapt to this change will undoubtedly gain a competitive edge in the future market!
*Note: For professional sterilizing filtration validation, PDA TR26 compliance consulting, and integrity testing support,